Contact this trialFirst, we need to learn more about you.
VEGF Inhibitor
Cabozantinib + Dostarlimab for Gynecologic Cancers
Recruiting1 awardPhase 1 & 2
Birmingham, Alabama
This trial tests a combination of two drugs, Cabozantinib and Dostarlimab, for patients with recurrent gynecologic carcinosarcoma. Cabozantinib works by blocking proteins that help tumors grow blood vessels, while Dostarlimab helps the immune system attack cancer cells. The goal is to improve treatment effectiveness by using both drugs together.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service